FDA rules Effexor XR journal ad misleading
Pharma Compliance Alert, December 19, 2007
The FDA ruled a professional journal ad for Wyeth's Effexor XR misbrands the product because it unsubstantiated superiority claims and minimizes risks associated with taking Effexor, according to a warning letter posted on the FDA's Web site last week.
According to the FDA, claims made in the ad are misleading because the studies they are based on were not properly designed. Other claims in the ad do not have supporting references, but add to the misleading nature of the advertisement.
The FDA also cited Wyeth for improperly claiming the number of patients treated with Effexor and Effexor XR because the data does not identify unique patients.
The FDA wants Wyeth to stop using the ad and submit a letter stating how the company plans to discontinue use of the material, as well as "a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective messages."
Click here to read the FDA's warning letter.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- Capturing all necessary codes for IUD insertion and removal can be challenging
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- HIPAA Q&A: Level of encryption needed for email
- OB services: Coding inside and outside of the package
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q/A. One injection code or two?
- What does case-mix index mean to you?
- ED-to-inpatient transfers are flawed with safety gaps
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Searched